A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sapanisertib (Primary) ; Pazopanib
Indications Leiomyosarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Sarcoma; Synovial sarcoma
Focus Adverse reactions; Therapeutic Use

27 Jul 2022 Status changed from active, no longer recruiting to discontinued.
31 May 2020 The protocol was amended after 4 of the first 12 subjects randomized to Pazopanib experienced > grade 3 toxicity, to begin at Pazopanib 400 mg, allowing titration to 800 per investigator discretion, as per the Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com